|
Market Closed -
OTC Markets
15:58:17 2023-09-07 EDT
|
5-day change | 1st Jan Change | ||
| 120,000.00 USD | -.--% |
|
-20.00% | -20.00% |
| 22-01-20 | Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P Global BMI Index | CI |
| 22-01-20 | Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P TMI Index | CI |
| Market Cap | 51.95M 46.45M 42.98M 38.91M 72.83M 4.94B 74.02M 517M 205M 2.59B 195M 191M 8.18B | P/E 2019 * |
-
| P/E 2020 | - |
|---|---|---|---|---|---|
| Enterprise Value | -99.99M -89.41M -82.72M -74.9M -140M -9.51B -142M -995M -394M -4.98B -375M -367M -15.75B | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
96% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 week | -20.00% | ||
| Current month | -20.00% | ||
| 1 month | -20.00% | ||
| 3 months | -20.00% | ||
| 6 months | -20.00% | ||
| Current year | -20.00% |
| 3 years | 3,000 |  | 399,160 |
| 5 years | 3,000 | | 399,160 |
| 10 years | 3,000 | | 3,719,992 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Hearne
DFI | Director of Finance/CFO | 64 | 2018-11-18 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 12/1/21 | EcoR1 Capital, LLC
| Buy | Company | 6,073,551 | 15.7794% | |
| 11/22/21 | Tavistock Life Sciences Co. (Investment Management)
| Sell | Company | 400,000 | 1.0390% | |
| 11/17/21 | Tavistock Life Sciences Co. (Investment Management)
| Sell | Company | 1,000,000 | 2.5974% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -20.00% | -20.00% | -.--% | 53.25M | |
| +0.45% | +3.13% | +54.96% | +125.16% | 1,135B | |
| +0.94% | +4.93% | +39.86% | +78.72% | 635B | |
| +0.39% | +1.44% | +25.77% | +97.48% | 505B | |
| +1.43% | +4.31% | +46.20% | +67.12% | 378B | |
| -3.21% | -2.10% | +60.72% | +33.22% | 358B | |
| -0.41% | +2.64% | +22.48% | +49.82% | 295B | |
| +0.23% | +3.66% | +2.57% | +23.69% | 266B | |
| +1.22% | +4.63% | +52.40% | +64.85% | 237B | |
| +1.70% | +3.67% | +31.21% | +102.15% | 193B | |
| Average | +0.24% | +1.76% | +31.62% | +64.22% | 400.37B | |
| Weighted average by Cap. | +0.42% | +2.44% | +41.40% | +83.61% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -112M -99.99M -92.51M -83.76M -157M -10.64B -159M -1.11B -440M -5.56B -420M -411M -17.62B | -126M -113M -105M -94.64M -177M -12.02B -180M -1.26B -498M -6.29B -474M -464M -19.91B |
| Net Debt | -178M -160M -148M -134M -250M -16.97B -254M -1.78B -703M -8.88B -670M -655M -28.11B | -152M -136M -126M -114M -213M -14.46B -216M -1.51B -598M -7.56B -570M -558M -23.94B |
Employees
145
Sector
Pharmaceuticals
- Stock Market
- Stocks
- ODTC Stock
Select your edition
All financial news and data tailored to specific country editions
